A Study of ARRY-371797 in Patients With Osteoarthritis of the Knee
Public ClinicalTrials.gov record NCT01366014. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 2 study, involving a 4-week treatment period, designed to test the ability of investigational study drug ARRY-371797 to reduce pain in patients with moderate to severe pain due to osteoarthritis (OA) of the knee, and to further evaluate the drug's safety. Approximately 150 patients from the US will be enrolled in this study.
Study identification
- NCT ID
- NCT01366014
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 157 participants
Conditions and interventions
Conditions
Interventions
- ARRY-371797, p38 inhibitor; oral Drug
- Oxycodone hydrochloride (HCl) extended release (ER), opioid agonist; oral Drug
- Placebo; oral Drug
Drug
Eligibility (public fields only)
- Age range
- 40 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2011
- Primary completion
- May 31, 2012
- Completion
- May 31, 2012
- Last update posted
- Oct 13, 2020
2011 – 2012
United States locations
- U.S. sites
- 13
- U.S. states
- 9
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Phoenix | Arizona | — | — |
| Pfizer Investigational Site | Fort Lauderdale | Florida | 33316 | — |
| Pfizer Investigational Site | Pinellas Park | Florida | 33781 | — |
| Pfizer Investigational Site | Sarasota | Florida | 34232 | — |
| Pfizer Investigational Site | Watertown | Massachusetts | — | — |
| Pfizer Investigational Site | Olive Branch | Mississippi | 38654 | — |
| Pfizer Investigational Site | Charlotte | North Carolina | — | — |
| Pfizer Investigational Site | Raleigh | North Carolina | — | — |
| Pfizer Investigational Site | Winston-Salem | North Carolina | — | — |
| Pfizer Investigational Site | Duncansville | Pennsylvania | 16635 | — |
| Pfizer Investigational Site | Austin | Texas | — | — |
| Pfizer Investigational Site | Salt Lake City | Utah | — | — |
| Pfizer Investigational Site | Kenosha | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01366014, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 13, 2020 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01366014 live on ClinicalTrials.gov.